NCT05239832View on ClinicalTrials.gov

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

PHASE2UnknownINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

September 29, 2021

Study Completion Date

August 5, 2022

Conditions
COVID-19 Pandemic
Interventions
BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Trial Locations (1)

519000

The Fifth Peoples' Hospital of Zhuhai, Zhuhai

Sponsors
All Listed Sponsors
lead

Livzon Pharmaceutical Group Inc.

INDUSTRY